Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs
- 1 May 2008
- journal article
- review article
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 158 (7-8) , 195-199
Abstract
The primary aim of the management of ankylosing spondylitis (AS) is symptomatic relief and prevention of structural changes and functional decline by both pharmaceutical and non-pharmaceutical interventions. NSAIDs are frequently used, but often have adverse effects or may not be effective enough to alleviate complaints. NSAIDs and Coxibs provide comparable symptomatic relief. It has now become clear, however, that these drugs are also associated with increased cardiovascular risk, probably due to imbalance between Cox-1- and Cox-2-inhibition. Limited evidence suggests that continuous use of NSAIDs may retard progression of axial structural changes as compared to 'on-demand' usage of these drugs. A critical appraisal of a recent paper on this topic indicates that more evidence is needed before continuous use of NSAIDs or Coxibs can be recommended taking also into consideration the increase cardiovascular risks of these drugs.Keywords
This publication has 21 references indexed in Scilit:
- Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based surveyClinical Rheumatology, 2006
- Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugsAnnals of the Rheumatic Diseases, 2006
- Impaired endothelial function in patients with ankylosing spondylitisRheumatology, 2005
- Prospects for disease modification in ankylosing spondylitis: Do nonsteroidal antiinflammatory drugs do more than treat symptoms?Arthritis & Rheumatism, 2005
- Discontinuation of Nonsteroidal Anti-inflammatory Drug Therapy and Risk of Acute Myocardial InfarctionArchives of internal medicine (1960), 2004
- Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritisSeminars in Arthritis and Rheumatism, 2004
- The rise and decline of nonsteroidal antiinflammatory drug–associated gastropathy in rheumatoid arthritisArthritis & Rheumatism, 2004
- Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trialsBMJ, 2002
- NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.1998
- Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazoneScandinavian Journal of Rheumatology, 1976